Axsome Therapeutics (NASDAQ:AXSM) Given New $245.00 Price Target at Jefferies Financial Group

Axsome Therapeutics (NASDAQ:AXSM) had its price objective hoisted by Jefferies Financial Group from $200.00 to $245.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also issued reports on AXSM. Oppenheimer reiterated an “outperform” rating and set a $220.00 target price on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Robert W. Baird set a $209.00 price target on Axsome Therapeutics in a report on Tuesday, January 13th. Mizuho set a $217.00 price target on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $225.00 price target on shares of Axsome Therapeutics in a report on Monday, January 5th. Finally, Royal Bank Of Canada increased their price target on Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Nineteen analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $208.72.

Axsome Therapeutics Trading Up 0.8%

NASDAQ:AXSM opened at $187.35 on Tuesday. Axsome Therapeutics has a 12 month low of $86.99 and a 12 month high of $191.50. The firm has a fifty day simple moving average of $164.72 and a 200-day simple moving average of $137.10. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $9.44 billion, a P/E ratio of -40.12, a PEG ratio of 12.00 and a beta of 0.40.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. The firm’s revenue for the quarter was up 63.2% compared to the same quarter last year. On average, equities research analysts anticipate that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total value of $1,383,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark E. Saad sold 37,577 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the sale, the director owned 10,002 shares of the company’s stock, valued at $1,652,130.36. The trade was a 78.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 308,874 shares of company stock valued at $51,390,805 over the last three months. 22.40% of the stock is currently owned by company insiders.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after buying an additional 1,002 shares during the period. Jones Financial Companies Lllp lifted its position in Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after buying an additional 7,320 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after purchasing an additional 84,151 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Axsome Therapeutics during the first quarter valued at $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after buying an additional 17,250 shares during the period. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.